OCS Heart Perfusion Post-Approval Registry
Launched by TRANSMEDICS · Sep 8, 2021
Trial Information
Current as of July 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The OCS Heart Perfusion Post-Approval Registry is a study looking at how well the OCS Heart System works for preserving hearts from donors for heart transplant patients. It aims to gather more information about this system in real-life situations, especially for hearts from donors who have died from brain death (DBD) or donors whose hearts have stopped beating (DCD). This registry is currently active but not recruiting new participants.
To be eligible for this study, you need to be an adult who is receiving a heart transplant using a heart from a DBD or DCD donor that has been preserved with the OCS Heart System. However, you cannot have had another solid organ transplant, like a kidney or liver transplant, or be on kidney dialysis at the time of your heart transplant. If you are interested in this study, it’s important to know that it focuses on collecting information after the heart transplant to ensure the OCS Heart System is effective and safe in real-world settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult primary heart transplant recipients of DBD or DCD donor hearts perfused on the OCS Heart System.
- Recipient Exclusion Criteria:
- • Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant; or
- • On renal dialysis at time of transplant.
- Donor Exclusion Criteria (for DCD Donor Hearts only):
- • Warm ischemic time \> 30 minutes (warm ischemic time is defined as: Time from when mean systolic blood pressure (SBP) is \< 50 mmHg or peripheral saturation \< 70% to aortic cross-clamp and administration of cold cardioplegia in the donor).
About Transmedics
TransMedics is a pioneering medical technology company focused on transforming the organ transplant process through innovative solutions. With a commitment to improving patient outcomes, TransMedics has developed advanced organ preservation and transportation systems, notably the Organ Care System (OCS), which enables the preservation and assessment of donor organs in a more physiologically relevant environment. By leveraging cutting-edge technology, TransMedics aims to enhance the viability of organs for transplantation, ultimately expanding the donor pool and improving the lives of patients awaiting transplants. The company’s dedication to research and clinical trials underscores its mission to advance the field of transplantation and contribute to better healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Boston, Massachusetts, United States
Rochester, Minnesota, United States
Boston, Massachusetts, United States
Pittsburgh, Pennsylvania, United States
Valhalla, New York, United States
Durham, North Carolina, United States
Palo Alto, California, United States
Boston, Massachusetts, United States
Seattle, Washington, United States
Nashville, Tennessee, United States
Durham, North Carolina, United States
San Francisco, California, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Lexington, Kentucky, United States
Minneapolis, Minnesota, United States
Dallas, Texas, United States
Jacksonville, Florida, United States
San Antonio, Texas, United States
Minneapolis, Minnesota, United States
New Haven, Connecticut, United States
Los Angeles, California, United States
Chicago, Illinois, United States
Milwaukee, Wisconsin, United States
Bronx, New York, United States
New York, New York, United States
Dallas, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials